netakimab
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Mar 20, 2023 (NCT07277179)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068083 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06640517 | Phase 3 | Aug 8, 2024 | Biocad |
| NCT07008547 | Phase 3 | Jul 30, 2024 | Biocad |
| NCT07277179 | Phase 3 | Mar 20, 2023 | Biocad |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocad | For profit | 3 | 3 | 1 | 2023 |
1 organizations
Page 1 / 1